LDX

2.63%

3.7¢ lumos diagnostics holdings limited

Pretty much in agreement with you, especially with smaller...

First 94 Last

Share
Profile

Follow
Hawk70

1,216 Posts.

351

28/09/24

10:35

Post #: 75883821
Share

Originally posted by Chamara1987: ↑

There is a certain cohort (namely young patients without any morbidity) that present to tertiary ED that get a clinical assessment, but do not always warrant blood or imaging investigation (bood testing often takes >2 hours to return due to backlogs and we try not to radiate our youth when possible).

The hospitals I am familiar with no longer perform RAT testing, but perform 4plex rapid PCR testing (which solely assess for Covid/ Flu A&B/ RSV) but again takes 2 hours to return mostly due to lab backlogs).

Patients are returned to the ED waiting room after assessment to await tests if requested.

In an overrun ED with a full waiting room I can see Febridx being used to purely get people out the door with some rapid objective data.

While not good medicine, patients themselves often also want some form of objective evidence, which this could potentially be.

For sicker patients being considered for admission we would not just rely on a test such as Febridex, but rather a full blood count, a chest XR, a 4Plex rapid PCR test +/- extended viral panel(which tests for 4 more types of common viruses and returning overnight) +/- a qantitative CRP.

Febridx could potentially add addtional information, MxA. There are many other viruses we dont rest for that this could help suggest it was, but I think there would only be a very small cohort where my other tests didn't already determine a treatment path.

Regional hospitals(some a big as a 100 beds) survive on POC testing particularly overnight. Even blood tests are done via a POC blood gas machines and no XR capability overnight. I can certianly see a lot of use there.

Just my two cents and I have no idea if American hospitals work the same way.

Expand

Pretty much in agreement with you, especially with smaller hospital scenario.

However, I can't see a world where a consulting ED doctor would be happy to send a person home on a yes / no finger-prick test when presenting with symptoms warranting a FBS.

20 yrs ago sure, but in this age of Litigation?

Not a chance.

LDX Price at posting: 3.7¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

The winners & losers on market if negative gearing were gone

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

DEG

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

NAM

ACCC seeks Olam divestments before it can buy Namoi Cotton

ESR

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KAL

KalGold rolls out detailed aeromagnetic survey across Pinjin project

STK

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 3 more messages in this thread...

First 94 Last

Add LDX (ASX) to my watchlist

(20min delay)
Last 3.7¢		Change -0.001(2.63%)		Mkt cap ! $20.83M

Open	High	Low	Value	Volume
3.8¢	3.8¢	3.7¢	$33.89K	909.5K

Buyers (Bids)

No.	Vol.	Price($)
11	857775	3.7¢

Sellers (Offers)

Price($)	Vol.	No.
3.8¢	226848	4

View Market Depth

No.	Vol.	Price($)
11	857775	0.037
1	984984	0.036
4	1595609	0.035
5	759001	0.034
5	815593	0.033

Price($)	Vol.	No.
0.038	226848	4
0.039	1075175	6
0.040	1860769	6
0.041	200000	3
0.042	100000	1

Last trade - 16.10pm 27/09/2024 (20 minute delay)

LDX (ASX) Chart

Pretty much in agreement with you, especially with smaller...

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Pretty much in agreement with you, especially with smaller...

Top Stories

The winners & losers on market if negative gearing were gone

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

The market's shrugged at China's stimulus measures all year. Why is this one different?

Week 39 Wrap: What HotCopper’s watching; China’s new stimmy moves boost metals; Oz CPI drop

HotCopper users muse on De Grey's denial of Agnico Eagle takeover bid – but who are Agnico?

ACCC seeks Olam divestments before it can buy Namoi Cotton

Estrella first foreign entity to win tenements in Timor-Leste under new laws ahead of 2025 tenders

KalGold rolls out detailed aeromagnetic survey across Pinjin project

5.6g/t gold intercept at Serbia's Rogozna supports Strickland's hopes for high-grade core

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News